(Press-News.org) JACKSONVILLE, Fla. — Researchers at Mayo Clinic's campus in Florida have discovered a protein that is overly active in every human sample of kidney cancer they examined. They also found that an experimental drug designed to block the protein's activity significantly reduced tumor growth in animals when used alone. Combining it with another drug already used to treat the cancer improved the effectiveness of both.
The findings, reported in the April 30 online issue of Clinical Cancer Research, offer a much-needed potential new direction for the treatment of clear cell renal cell carcinoma, which accounts for almost 85 percent of kidney cancer cases in the United States. More than 57,000 diagnoses of kidney cancer occur yearly in the U.S. with greater than 13,000 deaths.
"There is a clear need for new therapies for this common cancer. With very few exceptions, patients inevitably become resistant to all available treatments," says the study's senior investigator, molecular biologist John Copland, Ph.D.
Their findings might be relevant to the treatment of other cancers, says Christina von Roemeling, the study's lead author. The protein they identified is produced by the stearoyl CoA desaturase 1 (SCD1) gene, which has also been found to be over active in a number of other cancers, including lung, stomach, breast, prostate, ovary and colon cancers.
"This is a gene that is highly active in a lot of other cancers and it may be that the agent we tested could provide new clinical avenues in those cancers as well," von Roemeling says.
The experimental drug, A939572, is a targeted inhibitor of SCD1 protein. "We found it to be incredibly specific to cancer cells in laboratory mice treated with the agent," Dr. Copland says. "But these are early days in the testing of this agent for cancer."
Not only is SCD1 active in some cancers, it also is being investigated for its role in promoting obesity and diabetes, the researchers say. Scientists are also testing A939572 as an antidote to those conditions.
The Mayo Clinic scientists performed a genome screen of tissue samples from 150 kidney cancer patient tissue samples, which represented all stages of cancer progression, to identify genes that are significantly overexpressed, compared to noncancerous tissue samples. SCD1 was one of their top finds.
They then disabled SCD1 in laboratory kidney cancer cells and found that the tumor cells stopped growing and a large percentage died.
Next, researchers tested A939572 and the federally approved kidney cancer drug temsirolimus. They found that using either agent alone cut tumor growth by up to 25 percent in mice studies, but using both drugs together, and at lower doses, reduced it 60 to 70 percent.
"The synergy between the drugs was very striking, suggestive of significant clinical benefit in patients," Dr. Copland says.
Von Roemeling says that SCD1 protein expression offers a novel molecular prognostic biomarker in kidney cancer that could guide therapy.
The study was funded by National Cancer Institute grants R01CA104505, R01CA136665 and R01CA104505-05S1; the David & Lois Stulberg Endowed Fund for Kidney Cancer Research; Mr. and Mrs. Ompal Chauhan Kidney Cancer Research Fund; Kidney Cancer Research at Mayo Clinic in Florida; James C. and Sarah K. Kennedy Mayo Clinic Research Career Development Award for Clinicians; Scheidel Foundation; Fraternal Order of Eagles Florida State Auxiliary, and a grant for rare cancers from Dr. Ellis and Dona Brunton.
###
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.com and http://www.mayoclinic.org/news.
Journalists can become a member of the Mayo Clinic News Network for the latest health, science and research news and access to video, audio, text and graphic elements that can be downloaded or embedded.
Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
2013-05-01
ELSE PRESS RELEASES FROM THIS DATE:
HRT improves muscle function
2013-05-01
Hormone replacement therapy (HRT) significantly improves muscle function – down to the muscle fibre level – in postmenopausal women, a new study published today [1 May] in The Journal of Physiology shows.
Some studies published over the last decade have led to negative publicity around HRT, a treatment used to relieve symptoms of menopause, resulting in many women being reluctant to use it. However this new study offers a positive outcome from the treatment.
Previous studies, monitoring walking speed and jumping height, have suggested that HRT reduces the impacts of ...
Cosmetic breast implants may adversely affect survival in women who develop breast cancer
2013-05-01
The authors stress that these findings should be interpreted with caution as some studies did not adjust for other potential confounding factors. They call for further investigations into the long term health effects of breast implants.
Cosmetic breast implants have become increasingly popular, but some studies have suggested that implants can make it more difficult to detect breast cancer at an early stage because they create shadows on mammograms that can obscure some breast tissue.
A team of researchers based in Canada wanted to find out whether the stage at which ...
Psychological trauma after miscarriage is more likely in women using assisted reproduction
2013-05-01
Subfertile women who conceive through assisted reproduction are more likely to experience a greater traumatic impact following early pregnancy loss compared with women who conceive naturally, suggests a new study published today (1 May) in BJOG: An International Journal of Obstetrics and Gynaecology.
Miscarriage is the most common complication of pregnancy affecting 20% of all clinically recognised pregnancies.
This study, conducted at Queen Mary Hospital, The University of Hong Kong, aimed to identify the psychological impact following a first trimester miscarriage ...
Neon exposes hidden ALS cells
2013-05-01
CHICAGO --- A small group of elusive neurons in the brain's cortex play a big role in ALS (amyotrophic lateral sclerosis), a swift and fatal neurodegenerative disease that paralyzes its victims. But the neurons have always been difficult to study because there are so few of them and they look so similar to other neurons in the cortex.
In a new preclinical study, a Northwestern Medicine® scientist has isolated the motor neurons in the brain that die in ALS and, for the first time, dressed them in a green fluorescent jacket. Now they're impossible to miss and easy to ...
Bizarre bone worms emit acid to feast on whale skeletons
2013-05-01
Only within the past 12 years have marine biologists come to learn about the eye-opening characteristics of mystifying sea worms that live and thrive on the bones of whale carcasses.
With each new study, scientists have developed a better grasp on the biology of Osedax, a genus of mouthless and gutless "bone worms" that make a living on skeletons lying on the seafloor. In the latest finding, scientists at Scripps Institution of Oceanography at UC San Diego describe how the wispy worms are able to carry out their bone-drilling activities. As published in the May 1 online ...
Study finds less-used regimen for treating children in Africa with HIV is more effective
2013-05-01
Philadelphia, April 30, 2013 — Researchers from The Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, along with colleagues at the Botswana-Baylor Children's Clinical Centre of Excellence, conducted the first large-scale comparison of first-line treatments for HIV-positive children, finding that initial treatment with efavirenz was more effective than nevirapine in suppressing the virus in children ages 3 to 16. However, the less effective nevirapine is currently used much more often in countries with a high prevalence ...
Researchers tackle collapsing bridges with new technology
2013-05-01
In this month's issue of Physics World, an international group of researchers propose a new technology that could divert vibrations away from load-bearing elements of bridges to avoid catastrophic collapses.
Michele Brun, Alexander Movchan, Ian Jones and Ross McPhedran describe a "wave bypass" technique that has many similarities to those being used by researchers looking to create Harry Potter-style invisibility cloaks, which exploit man-made materials known as metamaterials to bend light around objects.
Led by Movchan, who is at the University of Liverpool, the researchers ...
Behavior of seabirds during migration revealed
2013-05-01
The behaviour of seabirds during migration – including patterns of foraging, rest and flight – has been revealed in new detail using novel computational analyses and tracking technologies.
Using a new method called 'ethoinformatics', described as the application of computational methods in the investigation of animal behaviour, scientists have been able to analyse three years of migration data gathered from miniature tracking devices attached to the small seabird the Manx Shearwater (Puffinus puffinus).
The Manx Shearwater is currently on the 'amber' list of UK Birds ...
Sleep duration associated with higher colorectal cancer risk
2013-05-01
A new study is the first to report a significant positive association between long sleep duration and the development of colorectal cancer, especially among individuals who are overweight or snore regularly. The results raise the possibility that obstructive sleep apnea may contribute to cancer risk.
"Our current study adds to the very limited literature regarding the relationship between sleep duration and/or sleep quality and colorectal cancer risk," said lead author Xuehong Zhang, MD, ScD, instructor in the Department of Medicine at Harvard Medical School and associate ...
Researchers pinpoint upper safe limit of vitamin D blood levels
2013-05-01
Chevy Chase, MD––Researchers claim to have calculated for the first time, the upper safe limit of vitamin D levels, above which the associated risk for cardiovascular events or death raises significantly, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
There is increasing evidence that vitamin D plays a pivotal role in human physiology. Vitamin D deficiency has been linked to cardiovascular events and mortality, but previous studies have found supplementation fails to decrease mortality ...